Current epidemics, such as AIDS or flu, and the emergence of new threatening pathogens,
such as the one causing the current coronavirus disease 2019 (COVID-19) pandemic …

Interactions between host and pathogen proteins constitute an important aspect of both
infectivity and the host immune response. Different viruses have evolved complex …

The current therapeutic arsenal against viral infections remains limited, with often poor
efficacy and incomplete coverage, and appears inadequate to face the emergence of drug …

Since the onset of antiviral therapy, viral resistance has compromised the clinical value of
small-molecule drugs targeting pathogen components. As intracellular parasites, viruses …

Highlights•Antiviral innate immunity is regulated by changes in cellular proteins.•These
include changes in abundance, localisation, interaction and PTMs.•Viral immune evasion …

The interactions between human and viral proteins are pivotal in viral infection and host
immune responses. These interactions traverse different stages of the viral life cycle …

Early vaccine development for coronavirus disease 2019 (COVID-19) was possible thanks
to the prior knowledge that the main immunogenic protein of coronaviruses is the spike …

Covering: up to April 2014 The development of drugs with broad-spectrum antiviral activities
is a long pursued goal in drug discovery. It has been shown that blocking co-opted host …

Inhibition of host protein functions using established drugs produces a promising antiviral
effect with excellent safety profiles, decreased incidence of resistant variants and favorable …

The current paradigm for managing infectious diseases has targeted unique processes or
enzymes within pathogens. A serious disadvantage of this pathogen-directed drug targeting …